MRK - Summit lead asset approved in China for lung cancer
2024-06-01 08:19:05 ET
More on Akeso, Summit Therapeutics, etc.
- Summit Therapeutics Stock: Plunging Despite A Win?
- Summit: A Few Catalysts In Q2 Of 2024 To Carry The Tide
- Summit Therapeutics' Ivonescimab: Strong Buy Its Dual-Action Approach To Cancer
- Summit pares gains as ‘China-only’ trial beats Merck’s Keytruda (update)
- Summit lead asset beats Merck’s Keytruda in a first in lung cancer